Liu Guan-Feng, Zhao Qi-Gang, Si Lei, Cao Yin-Guang, Li Guang-Yao, Wang Le-Xin
Department of Technology Resources and Environment, Wuhan Engineering University, Hubei Province, 430070, PR China.
Clin Invest Med. 2009 Dec 1;32(6):E225. doi: 10.25011/cim.v32i6.10656.
The primary purpose of this study was to investigate the in vitro and in vivo effect of survivin interference RNA (siRNA) on non-small cell lung cancer.
Lentivirus was used as a vector to transfer siRNA into human lung cancer A549 cells. The proliferation of the cancer cells was assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The lentivirus-mediated siRNA was also injected into the transplanted A549 tumor tissues in mice. Tumour growth was assessed after 11 injections over a period of 21 days.
Compared with the placebo and the blank lentiviral vector groups, the siRNA treatment group had reduced cell growth rate following 4 days of the treatment (P < 0.01). The average size of the transplanted A549 tumours in the siRNA treatment group (0.75+/-0.16 cm3, n=8) was smaller than in the placebo (2.09+/-0.22 cm3, n=6) or the blank lentivrial vector groups (1.89+/-0.18 cm3, n=6) (P < 0.01). The tumour growth inhibition rate in the siRNA groups was 46.1%.
Lentivirus-mediated siRNA therapy inhibits the growth of human lung cancer cells in vitro. The siRNA therapy also suppresses the growth of the transplanted lung cancer in mice.
本研究的主要目的是调查生存素干扰RNA（siRNA）对非小细胞肺癌的体外和体内作用。
以慢病毒为载体将siRNA导入人肺癌A549细胞。通过MTT[3-（4,5-二甲基噻唑-2-基）-2,5-二苯基四氮唑溴盐]法评估癌细胞的增殖情况。还将慢病毒介导的siRNA注射到小鼠体内移植的A549肿瘤组织中。在21天内进行11次注射后评估肿瘤生长情况。
与安慰剂组和空白慢病毒载体组相比，siRNA治疗组在治疗4天后细胞生长速率降低（P<0.01）。siRNA治疗组移植的A549肿瘤平均大小（0.75±0.16 cm3，n = 8）小于安慰剂组（2.09±0.22 cm3，n = 6）或空白慢病毒载体组（1.89±0.18 cm3，n = 6）（P<0.01）。siRNA组的肿瘤生长抑制率为46.1%。
慢病毒介导的siRNA疗法在体外抑制人肺癌细胞的生长。siRNA疗法也抑制小鼠体内移植肺癌的生长。
